Home › Schizophrenia › NCT06911931
Visual Perception in Schizophrenia
RecruitingHealthy volunteers welcome
Visual Perception in Schizophrenia: Assessing Predictive Processing in the Earliest Stages of the Visual Cortical Hierarchy
Who can join
Ages 18 to 65 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * All Subjects * Aged 18-65 * 20/32 visual acuity or better (using in-house optical correction, if necessary) * An ability to speak English well enough to complete study assessments and to consent to the study * Subjects with Schizophrenia-Spectrum Disorder * Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5). * Subjects with Bipolar Disorder * Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5). Exclusion Criteria: * All subjects * Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following: * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent. * Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter); * Actively intoxicated, as shown via patient self-report or staff report; * Substance use disorder in the past 3 months; * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening); * Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation. * Being in a current manic state * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter). * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks; * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records) * Lazy eye or squint or other known ocular pathology * Healthy Control Subjects * Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure); * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Case-match Control Non-ill Subjects * Any lifetime psychotic disorder (as assessed by SCID/or SSD); * Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD) * Persistent threshold psychotic symptoms * History of psychiatric hospitalization; * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days * First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Bipolar Subjects * Persistent threshold psychotic symptoms
About the study
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
What is being tested
- EEG measure of visual processing (other)
Sponsor: University of Rochester · Participants: 84 · Started: Nov 3, 2025
Contact the study team
- Edmund Lalor, PhD · Phone: 585-275-3077
Official record on ClinicalTrials.gov — NCT06911931
Locations in the U.S.
| New York | University of Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.